Faculty
Oncology Division
Alphabetical list (active faculty):   
Haeseong Park

Haeseong Park, MD, MPH

Associate Professor

Department of Medicine

Oncology Division

Molecular Oncology

Clinical Interests

  • Upper gastrointestinal cancer

Research Interests

  • Phase 1 clinical trials
  • Cancer immunotherapy
  • Molecular targeted therapy

Contact

  • 314-454-5102 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Peer-reviewed Publications

  • Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus
    Trikalinos NA, Robinson CG, Park H
    JAMA Surg 2021 Sep 22; [Epub ahead of print]
  • Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial
    Kim H, Pedersen K, Olsen JR, Mutch MG, Chin RI, Glasgow SC, Wise PE, Silviera ML, Tan BR, Wang-Gillam A, Lim KH, Suresh R, Amin M, Huang Y, Henke LE, Park H, Ciorba MA, Badiyan S, Parikh PJ, Roach MC, Hunt SR
    Clin Colorectal Cancer 2021 Sep;20(3):e185-e193
  • A Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2 or STK11 Mutations
    Devarakonda S, Pellini B, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom MQ, Wu N, Waqar SN
    J Thorac Dis 2021 Jul;13(7):4054-4062
  • Phase 1 Study of M2698, a P70S6K/AKT Dual Inhibitor, in Patients With Advanced Cancer
    Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R
    J Hematol Oncol 2021 Aug 18;14(1):127
  • Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC
    M Grierson P, Park H
    JCO Oncol Pract 2021 Jul 23:OP2100451; [Epub ahead of print]
  • A Single-Institution Phase I Feasibility Study of Dose-Escalated IMRT for Non-Operative Locally Advanced Esophageal Carcinoma
    Vlacich G, Ballard A, Badiyan SN, Spraker M, Henke L, Kim H, Lockhart AC, Park H, Suresh R, Huang Y, Robinson CG, Bradley JD, Samson PP
    Clin Transl Radiat Oncol 2021 Jun 29;30:19-25
  • CtDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine
    Pellini B, Pejovic N, Feng W, Earland N, Harris PK, Usmani A, Szymanski JJ, Qaium F, Mudd J, Petty M, Jiang Y, Singh A, Maher CA, Henke LE, Park H, Ciorba MA, Kim H, Mutch MG, Pedersen KS, Tan BR, Hawkins WG, Fields RC, Chaudhuri AA
    JCO Precis Oncol 2021 Feb 12;5
  • Race and Ethnicity Representation in Clinical Trials: Findings From a Literature Review of Phase I Oncology Trials
    Camidge DR, Park H, Smoyer KE, Jacobs I, Lee LJ, Askerova Z, McGinnis J, Zakharia Y
    Future Oncol 2021 Aug;17(24):3271-3280
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
    Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M
    CheckMate 577 Investigators (Contributors include: Park H)

    N Engl J Med 2021 Apr 1;384(13):1191-1203
  • Author Correction: COVID-19 Vaccine Guidance for Patients With Cancer Participating in Oncology Clinical Trials
    Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V
    COVID19 and Cancer Clinical Trials Working Group

    Nat Rev Clin Oncol 2021 May;18(5):320
  • COVID-19 Vaccine Guidance for Patients With Cancer Participating in Oncology Clinical Trials
    Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V
    COVID19 and Cancer Clinical Trials Working Group

    Nat Rev Clin Oncol 2021 May;18(5):313-319
  • Immunity, Immunotherapy, and Rectal Cancer: A Clinical and Translational Science Review
    Otegbeye EE, Mitchem JB, Park H, Chaudhuri AA, Kim H, Mutch MG, Ciorba MA
    Transl Res 2021 May;231:124-138
  • A Phase I Trial of Temsirolimus and Erlotinib in Patients With Refractory Solid Tumors
    Park H, Williams K, Trikalinos NA, Larson S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan R, Luo J, Lockhart AC, Wang-Gillam A
    Cancer Chemother Pharmacol 2021 Mar;87(3):337-347
  • Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients With Relapsed Refractory Hodgkin Lymphoma
    Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA
    Clin Cancer Res 2020 Nov 1;26(21):5579-5587
  • Reply to T.J.A. Dekker
    Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S
    J Clin Oncol 2020 Oct 1;38(28):3351-3352
  • Margetuximab Plus Pembrolizumab in Patients With Previously Treated, HER2-Positive Gastro-Oesophageal Adenocarcinoma (CP-MGAH22-05): A Single-Arm, Phase 1b-2 Trial
    Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ
    CP-MGAH22-5 Study Group

    Lancet Oncol 2020 Aug;21(8):1066-1076
  • FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial
    Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC
    JAMA Oncol 2020 Aug 1;6(8):1231-1240
  • Targeting HER2 With Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
    Tsurutani J, Iwata H, Krop I, Janne PA, Doi T, Takahashi S, Park H, Redfern C, Tamura K, Wise-Draper TM, Saito K, Sugihara M, Singh J, Jikoh T, Gallant G, Li BT
    Cancer Discov 2020 May;10(5):688-701
  • Gastric Cancer With Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches
    Sanjeevaiah A, Park H, Fangman B, Porembka M
    Cancers (Basel) 2020 Mar 5;12(3)
  • Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer
    Chen B, Alvarado DM, Iticovici M, Kau NS, Park H, Parikh PJ, Thotala D, Ciorba MA
    Cancer Immunol Res 2020 Apr;8(4):451-464
  • Tolerability and Safety of EUS-Injected Adenovirus-Mediated Double-Suicide Gene Therapy With Chemotherapy in Locally Advanced Pancreatic Cancer: A Phase 1 Trial
    Lee JC, Shin DW, Park H, Kim J, Youn Y, Kim JH, Kim J, Hwang JH
    Gastrointest Endosc 2020 Nov;92(5):1044-1052
  • Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
    Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S
    J Clin Oncol 2020 Jun 10;38(17):1887-1896
  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I
    DESTINY-Breast01 Investigators (Contributors include: Park H)

    N Engl J Med 2020 Feb 13;382(7):610-621
  • Randomized Controlled Trial of High-Dose Versus Standard-Dose Vitamin D3 for Prevention of Aromatase Inhibitor-Induced Arthralgia
    Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa FO, Frith AE, Ma CX, Park H, Rigden CE, Suresh R, Ellis M, Kent Osborne C, Rimawi MF
    Breast Cancer Res Treat 2019 Sep;177(2):427-435
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA
    J Natl Compr Canc Netw 2019 Jul 1;17(7):855-883
  • Trastuzumab Deruxtecan (DS-8201a) in Patients With Advanced HER2-Positive Gastric Cancer: A Dose-Expansion, Phase 1 Study
    Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T
    Lancet Oncol 2019 Jun;20(6):827-836
  • Trastuzumab Deruxtecan (DS-8201a) in Patients With Advanced HER2-Positive Breast Cancer Previously Treated With Trastuzumab Emtansine: A Dose-Expansion, Phase 1 Study
    Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S
    Lancet Oncol 2019 Jun;20(6):816-826
  • Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
    Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL
    JAMA Oncol 2019 Mar 1;5(3):393-401
  • Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
    Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F
    Oncologist 2019 Feb;24(2):219-228
  • Updates on AKT inhibition in Estrogen Receptor Positive Breast Cancer
    Park H, Ma C
    Medical Research Archives 2018 Jan;6(1):1-13
  • Pacritinib to Inhibit JAK/STAT Signaling in Refractory Metastatic Colon and Rectal Cancer
    Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC
    J Gastrointest Oncol 2017 Dec;8(6):985-989
  • Progress in PD-1-Based Immunotherapy: New Mechanistic Insight May Provide Expanded Hope for Application to Colon and Gastrointestinal Cancers
    Park H, Chen B, Ciorba MA
    Gastroenterology 2017 Oct;153(4):1162-1163
  • Phase I Dose-Escalation Study of the mTOR Inhibitor Sirolimus and the HDAC Inhibitor Vorinostat in Patients With Advanced Malignancy
    Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F
    Oncotarget 2016 Oct 11;7(41):67521-67531
  • North Central Cancer Treatment Group N10C2 (Alliance): A Double-Blind Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes
    Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL
    Menopause 2015 Jun;22(6):627-32
  • Synergism Between Bosutinib (SKI-606) and the Chk1 Inhibitor (PF-00477736) in Highly Imatinib-Resistant BCR/ABL(+) Leukemia Cells
    Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S
    Leuk Res 2015 Jan;39(1):65-71
  • Disseminated Histoplasmosis in Peripheral Blood Smear
    Park H, Shafer D
    Blood 2014 Mar 6;123(10):1445
  • Strategies to Circumvent the T315I Gatekeeper Mutation in the Bcr-Abl Tyrosine Kinase
    Bose P, Park H, Al-Khafaji J, Grant S
    Leuk Res Rep 2013 Jan 1;2(1):18-20
  • Acute Changes in N-Terminal Pro-B-Type Natriuretic Peptide During Hospitalization and Risk of Readmission and Mortality in Patients With Heart Failure
    Michtalik HJ, Yeh HC, Campbell CY, Haq N, Park H, Clarke W, Brotman DJ
    Am J Cardiol 2011 Apr 15;107(8):1191-5
  • A Pilot Phase II Trial of Magnesium Supplements to Reduce Menopausal Hot Flashes in Breast Cancer Patients
    Park H, Parker GL, Boardman CH, Morris MM, Smith TJ
    Support Care Cancer 2011 Jun;19(6):859-63
  • A Systematic Review of Barriers and Interventions to Improve Appropriate Use of Therapies for Sickle Cell Disease
    Haywood C Jr, Beach MC, Lanzkron S, Strouse JJ, Wilson R, Park H, Witkop C, Bass EB, Segal JB
    J Natl Med Assoc 2009 Oct;101(10):1022-33
  • Usefulness of Cystatin C and Prognosis Following Admission for Acute Heart Failure
    Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ
    Am J Cardiol 2009 Aug 1;104(3):389-92
  • Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children
    Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB
    Pediatrics 2008 Dec;122(6):1332-42
  • Systematic Review: Hydroxyurea for the Treatment of Adults With Sickle Cell Disease
    Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB
    Ann Intern Med 2008 Jun 17;148(12):939-55
  • Hydroxyurea for the Treatment of Sickle Cell Disease
    Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S
    Evid Rep Technol Assess (Full Rep) 2008 Mar;(165):1-95

Invited Publications

  • Esophageal and Gastric Cancer
    Jin R, Park H
    In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review, 5th Edition (Morgensztern D, Govindan R, Devarakonda S, Trikalinos NA, Editors), Wolters Kluwer, Philadelphia, 2022
  • Esophageal and Gastric Cancer
    Jin RV, Navo K, Park H
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Emerging Therapeutic Options for Metastatic Exocrine Pancreatic Cancer
    Park H, Poklepovic A, Bose P
    In: Pancreas: Anatomy, Diseases and Health Implications, Nova Science Publishers, Inc., September 2012, pp 159-172
  • I Want to Know About Your Cancer: Storybook for Children With Parents With Cancer [Korean]
    Cho J, Park H, Kim Y
    Samsung Medical Center, Seoul, Korea, June 2008